ArQule Reports First Quarter 2016 Financial Results
04. Mai 2016 07:00 ET
|
ArQule, Inc.
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the first quarter of...
ArQule Provides Proprietary Pipeline Update for AKT Inhibitors
28. Januar 2016 07:30 ET
|
ArQule, Inc.
First cohort dosed in phase 1 trial with ARQ 092 in Proteus syndromeArQule receives Investigational New Drug approval for ARQ 751BURLINGTON, Mass., Jan. 28, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc....
ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092
17. November 2015 07:30 ET
|
ArQule, Inc.
ArQule receives orphan drug designation for ARQ 092 in Proteus syndrome BURLINGTON, Mass., Nov. 17, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) and the National Human Genome Research...
UPDATE -- ArQule Presents Data on Tivantinib and Proprietary Pipeline at AACR-NCI-EORTC Conference
09. November 2015 07:55 ET
|
ArQule, Inc.
Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...
ArQule Presents Data on Tivantinib and Propietary Pipeline at AACR-NCI-EORTC Conference
09. November 2015 07:30 ET
|
ArQule, Inc.
Data connects preclinical and clinical studies validating ArQule’s precision medicine strategy BURLINGTON, Mass., Nov. 09, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced the...
ArQule Reports Third Quarter 2015 Financial Results
04. November 2015 07:00 ET
|
ArQule, Inc.
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., Nov. 04, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the third quarter of...
ArQule to Present Data on Tivantinib, ARQ 087, ARQ 092, and ARQ 751 at AACR-NCI-EORTC Conference
27. Oktober 2015 07:30 ET
|
ArQule, Inc.
Single-agent and combination pre-clinical and clinical data supportive of on-going clinical trials BURLINGTON, Mass., Oct. 27, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced...
ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 and Next Generation AKT Inhibitor ARQ 751 in Oncology
15. Oktober 2015 16:00 ET
|
ArQule, Inc.
Pre-Clinical Data Supports the Use of AKT1 and PI3K Mutations as Biomarkers for the Company’s AKT Inhibitors BURLINGTON, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today...